193 related articles for article (PubMed ID: 17359484)
21. Role of sphingosine 1-phosphate receptor type 1 in lymphocyte egress from secondary lymphoid tissues and thymus.
Chiba K; Matsuyuki H; Maeda Y; Sugahara K
Cell Mol Immunol; 2006 Feb; 3(1):11-9. PubMed ID: 16549044
[TBL] [Abstract][Full Text] [Related]
22. Central nervous system-directed effects of FTY720 (fingolimod).
Miron VE; Schubart A; Antel JP
J Neurol Sci; 2008 Nov; 274(1-2):13-7. PubMed ID: 18678377
[TBL] [Abstract][Full Text] [Related]
23. Sphingosine-1-phosphate, FTY720, and sphingosine-1-phosphate receptors in the pathobiology of acute lung injury.
Natarajan V; Dudek SM; Jacobson JR; Moreno-Vinasco L; Huang LS; Abassi T; Mathew B; Zhao Y; Wang L; Bittman R; Weichselbaum R; Berdyshev E; Garcia JG
Am J Respir Cell Mol Biol; 2013 Jul; 49(1):6-17. PubMed ID: 23449739
[TBL] [Abstract][Full Text] [Related]
24. High-density lipoproteins and their constituent, sphingosine-1-phosphate, directly protect the heart against ischemia/reperfusion injury in vivo via the S1P3 lysophospholipid receptor.
Theilmeier G; Schmidt C; Herrmann J; Keul P; Schäfers M; Herrgott I; Mersmann J; Larmann J; Hermann S; Stypmann J; Schober O; Hildebrand R; Schulz R; Heusch G; Haude M; von Wnuck Lipinski K; Herzog C; Schmitz M; Erbel R; Chun J; Levkau B
Circulation; 2006 Sep; 114(13):1403-9. PubMed ID: 16982942
[TBL] [Abstract][Full Text] [Related]
25. Sphingosine-1-phosphate analogue FTY720 causes lymphocyte redistribution and hypercholesterolemia in ApoE-deficient mice.
Klingenberg R; Nofer JR; Rudling M; Bea F; Blessing E; Preusch M; Grone HJ; Katus HA; Hansson GK; Dengler TJ
Arterioscler Thromb Vasc Biol; 2007 Nov; 27(11):2392-9. PubMed ID: 17761943
[TBL] [Abstract][Full Text] [Related]
26. Accumulation of fingolimod (FTY720) in lymphoid tissues contributes to prolonged efficacy.
Sensken SC; Bode C; Gräler MH
J Pharmacol Exp Ther; 2009 Mar; 328(3):963-9. PubMed ID: 19074680
[TBL] [Abstract][Full Text] [Related]
27. Local application of FTY720 to the lung abrogates experimental asthma by altering dendritic cell function.
Idzko M; Hammad H; van Nimwegen M; Kool M; Müller T; Soullié T; Willart MA; Hijdra D; Hoogsteden HC; Lambrecht BN
J Clin Invest; 2006 Nov; 116(11):2935-44. PubMed ID: 17080194
[TBL] [Abstract][Full Text] [Related]
28. Sphingosine-1-phosphate: A bioactive lipid that confers high-density lipoprotein with vasculoprotection mediated by nitric oxide and prostacyclin.
Rodríguez C; González-Díez M; Badimon L; Martínez-González J
Thromb Haemost; 2009 Apr; 101(4):665-73. PubMed ID: 19350109
[TBL] [Abstract][Full Text] [Related]
29. The S1P receptor modulator FTY720 prevents the development of experimental colitis in mice.
Deguchi Y; Andoh A; Yagi Y; Bamba S; Inatomi O; Tsujikawa T; Fujiyama Y
Oncol Rep; 2006 Oct; 16(4):699-703. PubMed ID: 16969482
[TBL] [Abstract][Full Text] [Related]
30. Selective attenuation of Toll-like receptor 2 signalling may explain the atheroprotective effect of sphingosine 1-phosphate.
Dueñas AI; Aceves M; Fernández-Pisonero I; Gómez C; Orduña A; Crespo MS; García-Rodríguez C
Cardiovasc Res; 2008 Aug; 79(3):537-44. PubMed ID: 18411230
[TBL] [Abstract][Full Text] [Related]
31. Potent S1P receptor agonists replicate the pharmacologic actions of the novel immune modulator FTY720.
Hale JJ; Neway W; Mills SG; Hajdu R; Ann Keohane C; Rosenbach M; Milligan J; Shei GJ; Chrebet G; Bergstrom J; Card D; Koo GC; Koprak SL; Jackson JJ; Rosen H; Mandala S
Bioorg Med Chem Lett; 2004 Jun; 14(12):3351-5. PubMed ID: 15149705
[TBL] [Abstract][Full Text] [Related]
32. Targeting sphingosine-1-phosphate signalling for cardioprotection.
Kennedy S; Kane KA; Pyne NJ; Pyne S
Curr Opin Pharmacol; 2009 Apr; 9(2):194-201. PubMed ID: 19070545
[TBL] [Abstract][Full Text] [Related]
33. Attenuation of cell motility observed with high doses of sphingosine 1-phosphate or phosphorylated FTY720 involves RGS2 through its interactions with the receptor S1P.
Kohno T; Igarashi Y
Genes Cells; 2008 Jul; 13(7):747-57. PubMed ID: 18513330
[TBL] [Abstract][Full Text] [Related]
34. Sphingosine-1-phosphate and the immunosuppressant, FTY720-phosphate, regulate detrusor muscle tone.
Watterson KR; Berg KM; Kapitonov D; Payne SG; Miner AS; Bittman R; Milstien S; Ratz PH; Spiegel S
FASEB J; 2007 Sep; 21(11):2818-28. PubMed ID: 17449719
[TBL] [Abstract][Full Text] [Related]
35. Sphingosine-1-phosphate: a novel nonhypoxic activator of hypoxia-inducible factor-1 in vascular cells.
Michaud MD; Robitaille GA; Gratton JP; Richard DE
Arterioscler Thromb Vasc Biol; 2009 Jun; 29(6):902-8. PubMed ID: 19423865
[TBL] [Abstract][Full Text] [Related]
36. Immunosuppressive activity of FTY720, sphingosine 1-phosphate receptor agonist: II. Effect of FTY720 and FTY720-phosphate on host-versus-graft and graft-versus-host reaction in mice.
Kataoka H; Ohtsuki M; Shimano K; Mochizuki S; Oshita K; Murata M; Sugahara K; Sato N; Hoshino Y; Chiba K
Transplant Proc; 2005; 37(1):107-9. PubMed ID: 15808562
[No Abstract] [Full Text] [Related]
37. [A new therapeutic approach for autoimmune diseases by the sphingosine 1-phosphate receptor modulator, fingolimod (FTY720)].
Chiba K
Nihon Rinsho Meneki Gakkai Kaishi; 2009 Apr; 32(2):92-101. PubMed ID: 19404007
[TBL] [Abstract][Full Text] [Related]
38. Sphingosine 1-phosphate receptor agonism impairs skin dendritic cell migration and homing to secondary lymphoid tissue: association with prolonged allograft survival.
Lan YY; Tokita D; Wang Z; Wang HC; Zhan J; Brinkmann V; Thomson AW
Transpl Immunol; 2008 Nov; 20(1-2):88-94. PubMed ID: 18694829
[TBL] [Abstract][Full Text] [Related]
39. [New therapeutic approach for autoimmune diseases by the sphingosine 1-phosphate receptor modulator, fingolimod (FTY720)].
Chiba K
Yakugaku Zasshi; 2009 Jun; 129(6):655-65. PubMed ID: 19483408
[TBL] [Abstract][Full Text] [Related]
40. Sphingosine-1-phosphate signaling and the skin.
Herzinger T; Kleuser B; Schäfer-Korting M; Korting HC
Am J Clin Dermatol; 2007; 8(6):329-36. PubMed ID: 18039015
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
